Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

liposomal Bcl-2 antisense oligonucleotide BP1002

A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:L-Bcl-2 antisense oligonucleotide BP1002
liposomal Bcl-2 antisense BP1002
Code name:BP 1002
BP-100-1.02
BP1002
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search